One of the most significant operational shifts in the German liquid biopsy landscape in late 2025 is the move toward decentralized testing, allowing more local laboratories to perform complex molecular assays. Previously, samples often had to be sent to centralized hubs or even abroad, leading to longer turnaround times for critical results. Modern "plug-and-play" NGS platforms and automated...